Skip to main content
Arjan Diepstra
dr.

As a hematopathologist, I work on diagnostics of all types of hematological malignancies using a comprehensive panel of different techniques. Moreover, my main research interest involves Hodgkin lymphoma, with a strong focus on interactions between tumor cells and the microenvironment. In addition, I also have a long standing interest in genetic susceptibility. My areas of expertise are: immunology, tumor cell biology, genetic association studies and molecular diagnostics in pathology. I actively participate in international (EORTC) and national (HOVON) clinical trials.

Progression of a solitary plasmacytoma to multiple myeloma. A population-based registry of the northern Netherlands
Published in: British Journal of Haematology
Access to document 10.1111/bjh.14291 document
Plasmacytoma is characterized by a local accumulation of monoclonal plasma cells without criteria for multiple myeloma (MM). The current treatment regimen is local radiotherapy. However, more than 50% of patients develop MM within 2years after treatment. A population-based registry was consulted for the diagnosis of solitary plasmacytoma between 1988 and 2011. Progression to MM and prognostic features for progression to MM were scored, including hypoxia inducible factors (HIF), vascular endothelial growth factor (VEGF, also termed VEGFA) and micro-vessel density (MVD) expression in biopsy material. A total of 76...
Esther G. M. de Waal, Marnix Leene, Nic Veeger, Hanneke J. Vos, Francisca Ong, Wilma G. J. M. Smit, Sjoerd Hovenga, Mels Hoogendoorn, Marieke Hogenes, Max Beijert, Arjan Diepstra, Edo Vellenga
Studying the role of oncogenic mir-24-3p in hodgkin lymphom
Y. Yuan, J. Kluiver, J. Koerts, D. de Jong, Bea Rutgers, A. Diepstra, Lydia Visser, Anke Berg, van den
Mutations in CD58 and MYB in Hodgkin Lymphoma
F.R. Abdul Razak, A. Diepstra, D. Jong, J. Koerts, B. Rutgers, J. Kluiver, Lydia Visser, Anke Berg, van den
Mid-treatment TARC and mid-treatment FGD-PET predict for progression free survival in classical hodgkin lymphom
W. J. Plattel, Anke Berg, van den, Lydia Visser, A. Glaudemans, A. Diepstra, G. van Imhoff
Plasma vesicle-associated mirnas as therapy response biomarkers in hodgkin lymphom
D M. Pegtel, E. Drees, M. A. J. van Eijndhoven, N. J. Groenewegen, S. van Niele, R. Prins, S. R. Baglio, J.M. Zijlstra, H. van der Voorn, S. F. W. M. Libregts, M. H. Wauben, R. X. de Menezes, J. R. T. van Weering, R. Nieuwland, A. Diepstra, D. de Jong